文献速递消化、代谢与肾脏急症

卡西瑞单抗和 imdevimab 单抗皮下或静脉给药与 COVID-19 成人临床结局的相关性

Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
PubMed 文献 · JAMA Netw Open · 2022-04-01
一句话结论高危轻中度 COVID-19 门诊患者中,皮下注射卡西瑞单抗和 imdevimab 与未治疗相比 28 天住院或死亡风险降低(RR 0.48),与静脉给药结局相近。

这项前瞻性队列研究在美国学习型健康系统中纳入 2021 年 7 月 14 日至 10 月 26 日符合紧急使用授权的高危轻中度 COVID-19 门诊患者。皮下注射卡西瑞单抗和 imdevimab 600 mg/600 mg 单次给药者 28 天住院或死亡率为 3.4%,未治疗对照组为 7.0%(RR 0.48;95%CI 0.30-0.80;P=0.002)。皮下给药与静脉给药相比,28 天住院或死亡率为 2.8% vs 1.7%,调整风险差 1.5%(95%CI -0.6% 至 3.5%;P=0.16)。作者认为,结果为皮下单抗治疗的潜在扩大使用提供了初步证据,尤其在面临治疗能力或人员短缺的地区。

要点

  • 符合单抗治疗条件的高危轻中度 COVID-19 门诊患者中,皮下注射卡西瑞单抗和 imdevimab 600 mg/600 mg 单次给药者 28 天住院或死亡率为 3.4%(22/653),未治疗对照组为 7.0%(92/1306),RR 0.48(95%CI 0.30-0.80;P=0.002)。
  • 皮下给药(n=969)与静脉给药(n=1216)相比,28 天住院或死亡率为 2.8% vs 1.7%,调整风险差 1.5%(95%CI -0.6% 至 3.5%;P=0.16)。
  • 全部输液患者中,ICU 入住调整风险差 0.7%(95%CI -3.5% 至 5.0%),机械通气需求调整风险差 0.2%(95%CI -5.8% 至 5.5%),均无差异。
  • 皮下给药可能扩大门诊治疗能力和可执行给药的人员范围,但作者仅将其列为初步证据。

适用人群与场景

  • 美国学习型健康系统中 2021 年 7 月 14 日至 10 月 26 日的高危轻中度 COVID-19 症状门诊患者,符合紧急使用授权下的单抗治疗条件。
  • 另设符合条件但未治疗的对照组。
  • 皮下治疗组 969 例,平均(SD)年龄 53.8(16.7)岁,女性 547 例(56.4%);静脉治疗组 1216 例,平均(SD)年龄 54.3(16.6)岁,女性 672 例(54.4%)。

处置流程与药物剂量

  • 卡西瑞单抗和 imdevimab 联合单次剂量 600 mg 卡西瑞单抗加 600 mg imdevimab,皮下注射或静脉给药。

研究设计与关键结果

  • 前瞻性队列研究,纳入 1959 例匹配的轻中度 COVID-19 成人,比较皮下注射卡西瑞单抗和 imdevimab(n=969)与未治疗对照(n=1306):28 天住院或死亡率为 3.4%(22/653)vs 7.0%(92/1306),风险比 0.48(95%CI 0.30-0.80;P=0.002)。
  • 2185 例接受皮下(n=969)或静脉(n=1216)卡西瑞单抗和 imdevimab 的患者中,28 天住院或死亡率为 2.8% vs 1.7%,调整风险差 1.5%(95%CI -0.6% 至 3.5%;P=0.16)。
  • 全部输液患者中,ICU 入住调整风险差 0.7%(95%CI -3.5% 至 5.0%),机械通气需求调整风险差 0.2%(95%CI -5.8% 至 5.5%)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,皮下给予卡西瑞单抗和 imdevimab 与未治疗相比与住院和死亡减少相关,这些结果为皮下单抗治疗的潜在扩大使用提供了初步证据,尤其在面临治疗能力和/或人员短缺的地区。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous administration may expand outpatient treatment capacity and qualified staff available to administer treatment, but the association with patient outcomes is understudied.

OBJECTIVES: To evaluate whether subcutaneous casirivimab and imdevimab treatment is associated with reduced 28-day hospitalization and death compared with nontreatment among mAb-eligible patients and whether subcutaneous casirivimab and imdevimab treatment is clinically and statistically similar to intravenous casirivimab and imdevimab treatment.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study evaluated high-risk outpatients in a learning health system in the US with mild to moderate COVID-19 symptoms from July 14 to October 26, 2021, who were eligible for mAb treatment under emergency use authorization. A nontreated control group of eligible patients was also studied.

EXPOSURES: Subcutaneous injection or intravenous administration of the combined single dose of 600 mg of casirivimab and 600 mg of imdevimab.

MAIN OUTCOMES AND MEASURES: The primary outcome was the 28-day adjusted risk ratio or adjusted risk difference for hospitalization or death. Secondary outcomes included 28-day adjusted risk ratios and differences in hospitalization, death, a composite end point of emergency department admission and hospitalization, and rates of adverse events. Among 1959 matched adults with mild to moderate COVID-19, 969 patients (mean [SD] age, 53.8 [16.7] years; 547 women [56.4%]) who received casirivimab and imdevimab subcutaneously had a 28-day rate of hospitalization or death of 3.4% (22 of 653 patients) compared with 7.0% (92 of 1306 patients) in nontreated controls (risk ratio, 0.48; 95% CI, 0.30-0.80; P = .002). Among 2185 patients treated with subcutaneous (n = 969) or intravenous (n = 1216; mean [SD] age, 54.3 [16.6] years; 672 women [54.4%]) casirivimab and imdevimab, the 28-day rate of hospitalization or death was 2.8% vs 1.7%, which resulted in an adjusted risk difference of 1.5% (95% CI, -0.6% to 3.5%; P = .16). Among all infusion patients, there was no difference in intensive care unit admission (adjusted risk difference, 0.7%; 95% CI, -3.5% to 5.0%) or need for mechanical ventilation (adjusted risk difference, 0.2%; 95% CI, -5.8% to 5.5%).

CONCLUSIONS AND RELEVANCE: In this cohort study of high-risk outpatients with mild to moderate COVID-19 symptoms, subcutaneously administered casirivimab and imdevimab was associated with reduced hospitalization and death when compared with no treatment. These results provide preliminary evidence of potential expanded use of subcutaneous mAb treatment, particularly in areas that are facing treatment capacity and/or staffing shortages.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. McCreary EK, Bariola JR, Wadas RJ, et al. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open. 2022. PMID: 35412625. doi:10.1001/jamanetworkopen.2022.6920

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。